Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2003

View Archived Issues

Efficacy of oral recombinant L. lactis vector expressing the HIV Env gene as an HIV vaccine in mice

DakoCytomation licenses novel prostate cancer markers

Oral efficacy study completed for small-molecule inhibitor of PTP1B

Avidex and Dow to develop biotargeted radiopharmaceuticals for cancer

Phase I/II trial of bone graft product cleared to begin

Orphan drug status granted to Hemoxin for sickle cell disease

Progress reported in development of DCtag vaccine technology

Partial clinical hold on phase III Oncophage trials

ICAgen completes enrollment in phase II trial of ICA-17043

Acambis and Cangene collaborate on West Nile hyperimmune development

CAT and Xerion enter into drug development agreement

GenVec completes Diacrin merger

Aphios marine microorganism library to be tested against SARS

Axcan licenses Itax from Abbott

Quorex and Idec enter collaboration

Phase II doripenem trial completes enrollment ahead of schedule

Two series of semaphorin inhibitors identified by Sumitomo researchers

Adenosine A1 receptor allosteric enhancers claimed by U. of Virginia scientists

New glucocorticoids for inflammatory and allergic disorders covered by GSK patent

Muscagen presents novel adenosine A3 agonists with potential as cardioprotectants

Glucocorticoid receptor modulators for obesity, diabetes, psychiatric disorders, etc.

Kylix describes new Tie-2/KDR inhibitors and their use

Spermine analogue displays potent central antinociceptive effects in rat model

Efficacy of new NMDA NR2B antagonist in models of chronic and neuropathic pain

Antihyperalgesic effects of EP1 receptor antagonists

Pfizer to market olmesartan in markets in Asia, Oceania and Latin America

Preservation of beta-cell function following treatment with NN-414

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...